**Introduction**

Nasal delivery is considered to be a promising technique for the subsequent reasons: the nose has a large surface area available for drug absorption due to the coverage of the epithelial surface by numerous microvilli, the subepithelial layer is highly vascularized, the venous blood from the nose passes directly into the systemic circulation and therefore avoids the loss of drug by first-pass metabolism in the liver, it offers lower doses, more rapid attainment of therapeutic blood levels, quicker onset of pharmacological activity, fewer side effects, high total blood flow per porous endothelial basement membrane, it is easily accessible, and drug is delivered directly to the brain along the olfactory nerves (Illum et al., 1994; Kissel et al., 1998; Ridley et al., 1995).

Microspheres carriers prepared with numerous polymers are attracting attention for many years for sustained release. Current scenario of dosage form is managed release rate and site specific to develop new drug delivery system. Microspheres are part of this type of novel development of system (Woo et al., 2001; Capan et al., 2003; Gogel et al., 1998).

The achievement in this system is low due to shorter stay at absorption site and rare absorption of large molecules. This limitation is overcome by blend of bioadhesion properties to microspheres. Such microspheres improve the residence time and intimate contact with absorption site (Nagai et al., 1984; Illum et al., 1988; Schaefer et al., 2000; Swamy et al., 2012).

Microspheres carriers prepared with numerous polymers are attracting attention for many years for sustained release. Current scenario of dosage form is managed release rate and site specific to develop new drug delivery system. Microspheres are part of this type of novel development of system (Woo et al., 2001; Capan et al., 2003; Gogel et al., 1998).

The achievement in this system is low due to shorter stay at absorption site and rare absorption of large molecules. This limitation is overcome by blend of bioadhesion properties to microspheres. Such microspheres improve the residence time and intimate contact with absorption site (Nagai et al., 1984; Illum et al., 1988; Schaefer et al., 2000; Swamy et al., 2012).

**Material and methods**

**Drug and chemicals**

The drug Metoclopramide hydrochloride was obtained as gift sample from Ind-Swift Ltd. Haryana, India. The mucoadhesive polymers used were chitosan (CIFT, Kochin, India)
The particle size and shape of the microspheres of different particle size analysis. Characterization of prepared microspheres (Thanoo et al., 1992).

In an equal volume of sodium alginate solution, by means of a 30mL of petroleum ether, and span 80 (3%; w/w) was emulsified. The external oil phase, containing 70mL of liquid vaseline, was dispersed in 60 ml of the suspension medium containing mineral oil/petroleum ether (60/40, ml) mixture and 1ml of span 80 as an emulsifier. The suspension medium was stirred (Remi stirrer, Mumbai, India) at constant speed for 10 minutes and 1ml of glutaraldehyde was added. Cross-linking of the microspheres was carried out by adding 1-2 ml of 25% glutaraldehyde and further stirring the dispersion for 20 min at room temperature(Bregnic et al., 2000).

**Chitosan microspheres**

The microspheres were prepared by the suspension cross linking method. Chitosan (about 200 mg) was dissolved in 10 ml 5% acetic acid solution and this solution (1:5 drug: polymer) dispersed in 60 ml of the suspension medium containing mineral oil/petroleum ether (60/40, ml) mixture and 1ml of span 80 as an emulsifier. The suspension medium was stirred (Remi stirrer, Mumbai, India) at constant speed for 10 minutes and 1ml of glutaraldehyde was added into the medium and moving persistent. With subsequent addition of 0.5 ml of glutaraldehyde after 30 min into the suspension medium, stirring were continued. At the end of 1 hour, stirring was stopped and the Chitosan microspheres were washed several times with petroleum ether, 5% sodium bisulphate solution and acetone, (consecutively) and then dried in an oven 65 °C (Bregnic et al., 2000).

**Sodium alginate microspheres**

The microspheres were prepared by cross linking of sodium alginate, participating in the aqueous internal phase of the primary emulsion with calcium ions (CaCl solution 10 % w/w). The supernatant is decanted, the sediment was washed with distilled water (200mL) 3 times and the microspheres was filtered and dried at 37 ºC, until they reached a constant weight .

The above bovine serum albumin dispersion was added to the continuous phase (10ml) which was a mixture of liquid paraffin and petroleum ether (6:4 v/v). The two phases were mixed in a vortex shaker for 5 min, to obtain a water-in-oil emulsion. Cross-linking of the microspheres was carried out by adding 1-2 ml of 25% glutaraldehyde and further stirring the dispersion for 20 min at room temperature(Bregnic et al., 2000).

% Entrapment efficiency = (Actual drug content/ theoretical drug content) ×100.

**In-vitro release studies**

**Ex- vivo nasal perfusion studies**

The rats (200-225 g) were anaesthetized by intraperitoneal injection of pentobarbitone sodium (30-50 mg/kg body weight). After an incision is made in the neck, trachea was cannulated with a polyethylene tube. The passage of the nasopalatine tract was sealed to prevent drainage of drug solution from nasal cavity through the nostril or through the esophagus cannulation tubing. During perfusion, a funnel was placed between the nasal cavity and reservoir to minimize loss of drug solution. The drug solution/suspension of microspheres, which was held in a reservoir maintained at 37±0.5°C, was circulated through the nasal cavity of the rat by means of a peristaltic pump. The perfusion solution/suspension of microspheres passed out of the nostrils, through the funnel, and returned to the reservoir, where the solution was stirred constantly with a magnetic stirrer. The amount of drug absorbed was determined by measuring the initial and final drug concentration of the perfusing solution. When all possible...
outlets in the rat nasal region were blocked following surgical preparation, the only possible passage for the drug to be absorbed and transported into the systemic circulation was by penetration and/or diffusion through the nasal mucosa (Illing et al., 1994; Patel et al., 2004).

**Statistical data analysis**

Results of ex-vivo experiments are reported as SEM (n= 5). Statistical tests of significance were performed using (Graph Pad in stat 3 software), differences were considered to be statistical significant when p< 0.05 using a two-tailed unpaired test (Deasy et al., 1994; Gavini et al., 2006).

**Results and discussion**

Albumin, chitosan and sodium alginate microspheres were prepared by emulsion solvent evaporation method. The particle size of microspheres was determined by optical microscopy. The average particle size was found to be in range of batches A3, C4 and SA6, 10 to 60µ, 1-20µ and 1-50µ respectively. Chitosan polymer showed spherical nature of microspheres as illustrated in figure. It was studied with escalating the concentration of polymers particle size improves. Above mean particle size of different polymers was found with at concentration of 24%, 5% and 2%. The particle size of microspheres above and lower than optimum concentration demonstrates coalescence of droplets. The preparation of different polymers microspheres occupied with upholding at 20 to 25°C.

**Optical microscopy of selected batches**

Shape and surface morphology were considered with microscopy. Pictures of different polymers were indicated showed nearly spherical and smooth surface (Figure 1). On the basis of particle size distribution the selected batches (form six batches of each polymer) of albumin, chitosan and alginate microspheres is depicted in table 1.

**Mucoadhesive properties**

The microspheres were evaluated for mucoadhesive activity by *In-vitro* wash off test. Adhesion property was evaluated through USP/IP/BP disintegration apparatus wherein container filled with 1.2pH buffer solution. The microspheres sticking to the tissue were measured in form of numbers of particles stand by after 30 minutes, 1 hour and at 4 hr. the calculation show that batch A3, C4 and SA6 presented maximum 75% mucoadhesion as compare to other batches (Table 2).

*In-vitro* wash off test among percentage of mucoadhesion and time in hours of A3, C4 and SA6 batches is shown in figure 2.

<table>
<thead>
<tr>
<th>Batch No.</th>
<th>Polymer solution (w/v)</th>
<th>Polymer: pet. Ether ratio</th>
<th>Drug: polymer ratio</th>
<th>%age of Emulsifying agent (w/w)</th>
<th>Cross linking agent for each 10ml</th>
<th>Time of stirring (minutes)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A2</td>
<td>24%</td>
<td>7:3</td>
<td>1:2</td>
<td>0.4</td>
<td>2</td>
<td>60</td>
</tr>
<tr>
<td>A3</td>
<td>24%</td>
<td>7:3</td>
<td>1:2</td>
<td>0.4</td>
<td>4</td>
<td>30</td>
</tr>
<tr>
<td>C2</td>
<td>2%</td>
<td>6:4</td>
<td>1:5</td>
<td>0.4</td>
<td>1</td>
<td>60</td>
</tr>
<tr>
<td>C4</td>
<td>2%</td>
<td>6:4</td>
<td>1:5</td>
<td>0.4</td>
<td>2</td>
<td>60</td>
</tr>
<tr>
<td>S.A. 5</td>
<td>4%</td>
<td>6:4</td>
<td>1:5</td>
<td>0.3%</td>
<td>10</td>
<td>20</td>
</tr>
<tr>
<td>S.A. 6</td>
<td>5%</td>
<td>6:4</td>
<td>1:5</td>
<td>0.3%</td>
<td>10</td>
<td>20</td>
</tr>
</tbody>
</table>

**Figure 1.** (a) Albumin microspheres (b) Chitosan microspheres and (c) Sodium Alginate microspheres
Incorporation efficiency

50 mg of drug-loaded Microspheres were digested in 10 to 25ml of 7.4pH buffer solution for 24 hrs. at room temperature (25 °C) to release any entrapped drug. The supernatant layer was removed and diluted 10 times. The actual drug content was found by Spectrophotometry at 272nm. Incorporation efficiency was calculated using the following formula

\% entrapped drug = (Actual drug content/ theoretical drug content) × 100 (Table 3).

Table 3. Incorporation efficiency of drug in different batches

<table>
<thead>
<tr>
<th>Batch Code</th>
<th>Drug: polymer ratio</th>
<th>% Drug content</th>
</tr>
</thead>
<tbody>
<tr>
<td>A3</td>
<td>1:2</td>
<td>66.55± 0.003</td>
</tr>
<tr>
<td>C4</td>
<td>1:5</td>
<td>75.94± 0.002</td>
</tr>
<tr>
<td>SA6</td>
<td>1:5</td>
<td>63.05± 0.003</td>
</tr>
</tbody>
</table>

In vitro release studies

The dissolution studies of selected batches of microspheres were carried out in 250 ml phosphate buffer of pH 7.4, rpm 50 at 272nm. The maximum amount of drug released in 6 hours was found to be 95, 98.1 and 88 of batches A3, C4 and SA6 (Table 4). % Cumulative release of drug from batches A3, C4 and SA6 is given in figure 3.

Stability Studies

A stability study of drug was done for different batches and was stable after 3 months of degradation studies of metoclopramide hydrochloride and maintained for period.

Conclusions

The best entrapment was achieved in chitosan microspheres i.e. 91.95%. By, above results it was concluded that chitosan microspheres showed reproducible results and with good surface morphology. The above study results that metoclopramide hydrochloride microspheres appropriate system for nasal delivery.

Conflicts of interest: Nil

References


